A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Report

PURPOSE: To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and biologic effects of cixutumumab administered in combination with temsirolimus to children with refractory solid tumors. EXPERIMENTAL DESIGN: Cixutumumab and temsirolimus were administered in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Fouladi, Maryam, Perentesis, John P., Wagner, Lars M., Vinks, Alexander A., Reid, Joel M., Ahern, Charlotte, Thomas, George, Mercer, Carol A., Krueger, Darcy A., Houghton, Peter J., Doyle, L. Austin, Chen, Helen, Weigel, Brenda, Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4454739/
https://ncbi.nlm.nih.gov/pubmed/25467181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0595
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados